Q2 2025 Theralase Technologies Inc Earnings Call Transcript
Good morning and thank you for joining us today. I'm Matthew Perraton, Investor Relations Manager at Theralase Technologies Inc. And it's a pleasure to welcome our shareholders and stakeholders to our second quarter 2025 investor conference call.
We appreciate your ongoing support as Falas continues to advance through a pivotal phase of its transformation.
The 3rd quarter of 2025 was planned to mark the completion of patient enrollment in a registrational bladder cancer study, but due to the summer holiday schedule, the 90 patient to be enrolled will be in the fourth quarter of 2025.
Completion of this milestone will allow us to complete our 15 month patient follow up in the 4th quarter of 2026. This in turn allows us the op opportunity to file a new drug application for marketing approval with Health Canada and the FDA by the end of 2026, the beginning of 2027.
Assuming the FDA grants us prior review for the NDA and we meet all regulatory guidelines, we would be granted marketing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
